(Q37853882)

24 August 2017

Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection (English)

1 reference

24 August 2017

0 references

1 reference

Danica K Hickey

1

1 reference

24 August 2017

Frank E Aldwell

series ordinal

2

1 reference

24 August 2017

Kenneth W Beagley

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

21 December 2009

1 reference

24 August 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

24 August 2017

28

1 reference

24 August 2017

7

1 reference

24 August 2017

1668-1672

1 reference

Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

7 January 2021

Chlamydial salpingitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Oral tolerance, an active immunologic process mediated by multiple mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Efficacy of oral and parenteral routes of Mycobacterium bovis bacille Calmette-Guerin vaccination against experimental bovine tuberculosis in white-tailed deer (Odocoileus virginianus): a feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Influenza specific antibodies in the female genital tract of mice after oral administration of live influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Antibody responses and infertility in mice following oral immunization with attenuated Salmonella typhimurium expressing recombinant murine ZP3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Lipases and lipolysis in the human digestive tract: where do we stand?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

The roles of membrane microdomains (rafts) in T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Location is everything: lipid rafts and immune cell signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Response of endocytosis to altered fatty acyl composition of macrophage phospholipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Endogenous versus exogenous fatty acid availability affects lysosomal acidity and MHC class II expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Fatty acid inhibition of concanavalin A-stimulated lymphocyte proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

Fatty acid inhibition of lipopolysaccharide-stimulated B lymphocyte proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.010

10.1016/J.VACCINE.2009.12.010

7 January 2021

Identifiers

DOI

1 reference

24 August 2017

1 reference